natural killer cell therapy News
-
CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems
CD Formulation, a reputable contract research organization (CRO) based in New York, has become a trusted partner for many pharmaceutical companies around the world seeking innovative drug formulation methods and solutions. Recently, CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the development of cutting-edge CAR-T and CAR-NK cells for ...
-
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab as a first-line treatment in advanced HER2/neu positive ...
-
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM) An ongoing Phase 1 portion of a Phase 1/2a trial of genetically modified placental-derived natural killer cell therapy candidate, CYNK-101, in HER2+ gastric cancer All three ongoing clinical programs have been ...
-
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, in ...
-
G-CON Supplies the Cleanroom Infrastructure for Cytoimmune Therapeutics, Inc.
G-CON, the leader in prefabricated, flexible cleanroom solutions, recently supplied the cleanroom infrastructure for CytoImmune Therapeutics, Inc. (CytoImmune), a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies. G-CON PODs were built in College Station and have been shipped and integrated into CytoImmune’s ...
-
New Culture Medium Supports Expansion of Natural Killer Cells for Cell and Gene Therapies
Thermo Fisher Scientific today announced the launch of Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, a GMP-manufactured cell culture medium that supports large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells. This is the first medium from Thermo Fisher specifically designed to support expansion of NK cells for cell therapy ...
-
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some ...
-
Sanofi completes Kiadis acquisition
Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis (Euronext Amsterdam and Brussels: KDS) today jointly announce the successful completion of Sanofi’s acquisition of Kiadis, a clinical-stage biopharmaceutical company developing next generation ‘off-the-shelf’ NK cell-therapies. Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK-cells from a ...
-
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
Ongoing Phase 1 study of unmodified placental-derived natural killer (NK) cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) continues enrolling new cohorts to reflect adjustments to treatment regimen and dosing as outlined in December 2021 Ongoing Phase 1 study of CYNK-001 in glioblastoma multiforme (GBM) U.S. Food and Drug Administration (FDA) granted Fast Track ...
-
Immunai Raises $60M to Reprogram Immunity
Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel immunological insights that lead to the discovery and development of more effective and targeted immunotherapies. The Series A round was led by ...
By Immunai
-
Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its placental-derived allogeneic genetically modified NK cell therapy program (CYNK-101) and its placenta-derived allogeneic CAR-NK cell therapy program (CAR19-CYNK), respectively. The Company reported its findings in two poster presentations at the 63rd American Society of ...
-
Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11TH Annual Global Healthcare Conference on Thursday, February 17TH, at 2:20 pm ET. A live webcast of the discussion will be ...
-
Caribou Biosciences to Participate in Citi’s 16th Annual BioPharma Virtual Conference
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a panel discussion entitled “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy” on Thursday, September 9, ...
-
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40TH Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. A live webcast of the presentation will be accessible ...
-
Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
Obsidian Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive ...
-
GI Innovation released passing of early clinical research of GI-101 in SITC, U.S.A
-SITC 2021, re-hosted face to face meeting for the first time in 2 years due to COVID-19…topic for overcoming tolerance of Immuno-oncology -International researchers pay attention to immuno-oncology GI-101’s material excellence that had the mechanism of overcoming tolerance GI Innovation revealed KEYNOTE-B59’s clinical research process of GI-101(CD80/IL-2 variant bispecific ...
-
Exclusive License Agreement With Case Western Reserve University for Core-NK Platform
Exclusive global license for CORE NK platform (CHM 0201) executed with Case Western Reserve University in Ohio Initial Phase 1 clinical trial results of the CORE NK platform (CHM 0201) were published demonstrating safety and encouraging activity in blood cancers and solid tumours One patient achieved a complete response that was sustained for over 15 months at time of publication Based on ...
-
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an AML murine model demonstrated anti-tumor efficacy; ...
By Affimed GmbH
-
Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences
Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells ISCT abstract describes scalable, reproducible, cGMP-ready CAR-NK manufacturing process to support planned clinical development of oncology pipeline candidates Senti Bio, a leading gene circuit company, today announced the acceptance of ...
-
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you